Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.44 USD
Change Today -0.17 / -4.71%
Volume 1.9M
IDRA On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 4:30 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

idera pharmaceuticals inc (IDRA) Key Developments

Idera Pharmaceuticals Appoints Mark J. Casey as General Counsel and Secretary of the Board of Directors

Idera Pharmaceuticals, Inc. has appointed Mark J. Casey as Senior Vice President, General Counsel and Secretary of the Board of Directors. Mr. Casey most recently served as Chief Administrative Officer, Senior Vice President, General Counsel and Secretary of Hologic Incorporated.

Idera Pharmaceuticals Enters into Strategic Clinical Research Alliance with The University of Texas MD Anderson Cancer Center to Advance Clinical Development of Intratumoral TLR9 Agonist in Combination with Checkpoint Inhibitors

Idera Pharmaceuticals, Inc. announced that the company has entered into a strategic clinical research alliance with The University of Texas MD Anderson Cancer Center to advance clinical development of intratumoral TLR9 agonist in combination with checkpoint inhibitors. IMO-2125 is a TLR9 agonist which has been evaluated subcutaneously in over 80 human subjects, was well tolerated, and was shown to induce immune responses. The company intends to initiate the first trial of the research alliance, a Phase 1/2 study to assess the safety and efficacy of Intratumoral IMO-2125 in combination with ipilimumab (a CTLA4 antibody) in patients with metastatic melanoma. In this trial, escalating doses of IMO-2125 will be administered intratumorally into a lesion, with a standard dosing regimen of ipilimumab. The primary objectives of the trial will be to determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLTs) of IMO-2125 when administered intratumorally in combination with ipilimumab, as well as to determine the efficacy of the combination utilizing the immune-related response criteria (irRC). The company has already filed and received FDA feedback to a Pre-Investigational New Drug Application (PIND) for IMO-2125 and intends to submit an Investigational New Drug application (IND) and initiate the clinical study in the second half of the year 2015. The trial will enroll approximately 45 patients. The company expects data to be available in 2016. The study will be led by Adi Diab, MD, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson. Additional trials as part of the broader, clinical research alliance are currently in the planning stages.

Idera Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 01:30 PM

Idera Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 01:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Vincent J. Milano, Chief Executive Officer, President and Director.

Idera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015

Idera Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported alliance revenue of $34,000 against $3,000 a year ago. Loss from operations was $12,523,000 against $8,973,000 a year ago. Net loss applicable to common stockholders was $12,481,000 or $0.12 per basic and diluted share against $9,146,000 or $0.12 per basic and diluted share a year ago.

Idera Pharmaceuticals, Inc., Annual General Meeting, Jun 08, 2015

Idera Pharmaceuticals, Inc., Annual General Meeting, Jun 08, 2015., at 14:00 Eastern Daylight. Location: 167 Sidney Street. Agenda: To elect two Class II directors to board of directors for terms to expire at the 2018 annual meeting of stockholders; to approve, by non-binding vote, executive compensation; to approve an amendment to 2013 Stock Incentive Plan; to ratify the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2015; and to transact any other business as may properly come before the 2015 annual meeting or any postponement or adjournment of the 2015 annual meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDRA:US $3.44 USD -0.17

IDRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDRA.
View Industry Companies
 

Industry Analysis

IDRA

Industry Average

Valuation IDRA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3,626.8x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2,969.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDERA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.